useful in cancer prevention, due to their ability to 'reactivate' the expression of epigenetically silenced genes, including those involved in differentiation, invasion and metastasis. Among the growing list of HDAC-inhibitors, the branched-chain fatty acid valproic acid (VPA) has been shown to possess distinct HDAC inhibitory properties and to affect the growth and survival of tumour cells in vitro and in vivo
. VPA is an established drug in the long-term therapy of epilepsy. It can be applied orally, negative side effects are rare and it demonstrates expedient pharmacokinetic properties.
VPA has been investigated in pre-clinical models of skin, breast, colon, liver, prostate, cervix and small cell lung cancer. Currently, the drug is in phase I trials [6, 7] for treatment of solid tumours.
To assess whether VPA might be of benefit in treating RCC patients, the potential of VPA to block growth properties of RCC cell lines in vitro and in vivo were investigated and the underlying mode of action explored. Also, VPA was combined with low-dosed IFN-␣ and the effects of the combination regimen compared to single drug application. The experimental strategy was based on earlier reports demonstrating that IFN-␣ may enhance VPA's potency both in vivo and in vitro [8] [9] [10] . 
VPA could be shown to potently block RCC tumour cell proliferation in vitro and prevent RCC tumour growth in vivo. VPA's activity is associated with reduction of HDAC and elevated acetylation of histones H3 and H4. Entry of RCC tumour cells into the S-phase of the cell cycle is delayed and the expression pattern of cell cycle regulating proteins modified by VPA. It is of particular interest that VPA-IFN-␣ combination induced stronger effects on RCC cell growth in vitro than

Tumour cell growth
Cell proliferation was assessed using the 3- (4,5- (Fig. 2, left) . The same phenomenon was observed after a 5-day pre-incubation period. VPA dose dependently (1 mM > 0.25 mM) reduced Caki-1 proliferation. The 5-day effects were more potent than the 3-day effects and became even stronger when VPA was applied in combination with IFN-␣ (Fig. 2, right) . (Fig. 3) . (Fig. 6, right) [11] .
Results
Inhibition of RCC cell proliferation by VPA
VPA and VPA-IFN-␣ combination increase histone H3 and H4 acetylation
VPA treatment inhibits progression of tumour xenografts
Tumour xenografts were established in athymic nu/nu mice using Caki-1 cells to evaluate the effects of VPA or VPA-IFN-␣ combination on RCC cell growth in vivo. Compared to the untreated animals, application of VPA significantly diminished the tumour volume, with reduction of 70% at day 46, compared to the control (Fig. 6). No body weight loss or diarrhoea was observed and all animals (treated as well as non-treated) survived. Western blot analysis revealed strong accumulation of p21 and bax in tissue specimens of VPA-treated animals
Fig. 4 Cell cycle analysis of synchronized Caki-1 cells, treated with IFN-␣, with low-(0.25 mM) or high-dosed (1 mM) VPA or with VPA-IFN-␣ combination. The phrase '3 days' is related to a 3-day VPA incubation, the phrase '5 days' is related to a 5-day VPA incubation. Controls remained untreated. The cell population at each specific checkpoint is expressed as percentage of the total cells analysed. One representative experiment out of three is shown.
Fig. 5 Western blot analyses of cell cycle proteins, listed in 'Materials and methods'. Synchronized Caki-1 cells were treated with IFN-␣, with low-(0.25 mM) or high-dosed (1 mM) VPA, with VPA-IFN-␣ combination or remained untreated (control). The phrase '3 days' is related to a 3-day VPA incubation, the phrase '5 days' is related to
VPA administered for 5 days was more potent than a 3-day application. Prolonged VPA exposure has been shown to be necessary to modify neuroectodermal tumour cells [12, 13] , and Xia et al. has suggested that chronic administration of VPA is required to achieve therapeutic benefits with prostate carcinoma [14] [17, 18] . In another study, cyclin D3 levels were significantly higher in ovarian tumours of low malignant potential than in ovarian adenocarcinomas, and absent cyclin D3 expression was an indicator of poor survival in the patient cohort [19] . Suppressive activity of cyclin D3 has also been reported in skin carcinogenesis [20] , in pancreatic adenocarcinomas [21] and prostate carcinoma [22] . In good accordance with our data, exposure of C6 glioma cells to VPA induced a marked up-regulation of cyclin D3 and decreased expression of the proliferating cell nuclear antigen, both of which are detectable in the G1-phase [23] .
Evidence has been provided that cyclin D3 expression positively correlates with Rb protein expression [19] . In fact, hypophosphorylated Rb is strongly involved in the repression of proliferation-associated genes [24] . Although Rb expression has not been analysed in an RCC cell culture model, aberrant Rb levels were detected in tissue specimens taken from RCC patients [18] . Recently, the short-chain fatty acid HDAC inhibitors tributyrin and sodium butyrate were demonstrated to enhance expression levels of hypophosphorylated Rb in prostate cancer [25] , and VPA was shown to induce G1 arrest in association with Rb up-regulation in human melanoma cells [26] [28] , and to suppress tumour angiogenesis in vivo [29] . However, a different VPA regimen may be required to treat other tumour types. Daily i.p. injections of 366 mg/kg VPA were necessary to inhibit gastrointestinal tumour growth in nu/nu mice [30] , and neuroblastoma xenograft studies were based on 400 mg/kg VPA [8, 31] (2) -C, whereas IFN-␣ on its own has little or no effect [9] . Most strikingly, VPA plus IFN-␣ synergistically inhibited growth of UKF-NB-3 xenograft tumours in nude mice and induced complete cures in two out of six animals, whereas single treatment merely inhibited tumour growth [8] . Furthermore, IFN-␣ has been documented to enhance the anti-angiogenic action of HDAC-inhibitors in neuroblastoma bearing transgenic mice [10] , and to potentiate the influence of HDAC-inhibitors on growth and invasion of lung and liver cancer cells [32, 33] .
A 
